Check for updates

OPEN ACCESS

EDITED BY Akiyoshi Shimura, Tokyo Medical University, Japan

REVIEWED BY Haitham Jahrami, Arabian Gulf University, Bahrain Anoop Kumar, Delhi Pharmaceutical Sciences and Research University, India

*CORRESPONDENCE Chee H. Ng ⊠ cng@unimelb.edu.au Qinge Zhang ⊠ zqe81@126.com Yu-Tao Xiang ⊠ xyutly@gmail.com

[†]These authors have contributed equally to this work

RECEIVED 04 August 2023 ACCEPTED 11 December 2023 PUBLISHED 08 January 2024

CITATION

Gui Z, Wang Y-Y, Li J-X, Li X-H, Su Z, Cheung T, Lok K-I, Ungvari GS, Ng CH, Zhang Q and Xiang Y-T (2024) Prevalence of poor sleep quality in COVID-19 patients: a systematic review and meta-analysis. *Front. Psychiatry* 14:1272812. doi: 10.3389/fpsyt.2023.1272812

COPYRIGHT

© 2024 Gui, Wang, Li, Li, Su, Cheung, Lok, Ungvari, Ng, Zhang and Xiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Prevalence of poor sleep quality in COVID-19 patients: a systematic review and meta-analysis

Zhen Gui^{1,2†}, Yue-Ying Wang^{2†}, Jia-Xin Li^{2†}, Xiao-Hong Li^{3†}, Zhaohui Su⁴, Teris Cheung⁵, Ka-In Lok⁶, Gabor S. Ungvari^{7,8}, Chee H. Ng⁹*, Qinge Zhang¹⁰* and Yu-Tao Xiang^{1,2}*

¹Unit of Psychiatry, Department of Public Health and Medicinal Administration, Faculty of Health Sciences, Institute of Translational Medicine, University of Macau, Macao SAR, China, ²Centre for Cognitive and Brain Sciences, University of Macau, Macao SAR, China, ³Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical School, Beijing, China, ⁴School of Public Health, Southeast University, Nanjing, China, ⁵School of Nursing, Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China, ⁶Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao SAR, China, ⁷Section of Psychiatry, University of Notre Dame Australia, Fremantle, WA, Australia, ⁸Division of Psychiatry, School of Medicine, University of Western Australia, Perth, WA, Australia, ⁹Department of Psychiatry, The Melbourne Clinic and St Vincent's Hospital, University of Melbourne, Richmond, VIC, Australia, ¹⁰Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China

Objective: The coronavirus disease (COVID-19) and the public health responses were associated with a huge health burden, which could influence sleep quality. This meta-analysis and systematic review examined the prevalence of poor sleep quality in COVID-19 patients.

Methods: PubMed, Web of Science, Embase, and PsycINFO were systematically searched from their respective inception to October 27, 2022. Prevalence rates of poor sleep were analyzed using a random effects model.

Results: Totally, 24 epidemiological and 12 comparative studies with 8,146 COVID-19 patients and 5,787 healthy controls were included. The pooled prevalence of poor sleep quality based on the included studies was 65.0% (95%CI: 59.56–70.44%, *I*² = 97.6%). COVID-19 patients had a higher risk of poor sleep quality compared to healthy controls (OR = 1.73, 95% CI: 1.30–2.30, p < 0.01, *I*² = 78.1%) based on the 12 comparative studies. Subgroup analysis revealed that COVID-19 patients in low-income countries (p = 0.011) and in studies using a lower Pittsburgh Sleep Quality Index score cut-off (p < 0.001) were more likely to have poor sleep quality. Meta-regression analyses revealed that being female (p = 0.044), older (p < 0.001) and married (p = 0.009) were significantly correlated with a higher risk of poor sleep quality while quality score (p = 0.014) were negatively correlated with the prevalence of poor sleep quality in COVID-19 patients.

Conclusion: Poor sleep quality was found to be very common in COVID-19 patients. Considering the negative effects of poor sleep quality on daily life, sleep quality should be routinely assessed and appropriately addressed in COVID-19 patients.

KEYWORDS

COVID-19, sleep quality, meta-analysis, prevalence, review

1 Introduction

The huge health burden caused by the coronavirus disease (COVID-19) pandemic and the strict public health measures (e.g., social isolation) were associated with adverse physical and mental health outcomes (1, 2) including poor sleep quality (3). For instance, studies found that SARS-CoV-2 may affect negatively sleep in COVID-19 patients via a direct effect on the central nervous system (CNS) (4), or due to other COVID-19 related symptoms, such as fever, headache, dyspnea, myalgia, throat pain, cough, gastrointestinal disturbance, fatigue, anxiety and depression (5, 6), all of which could lead to poor sleep quality (7). A cohort study of hospitalized COVID-19 patients in China showed that 90.2% experienced poor sleep quality based on the Pittsburgh Sleep Quality Index (PSQI) assessment (8).

Poor sleep quality can have a negative impact on health. A study of COVID-19 patients in Turkey showed that poorer sleep quality was associated with a longer duration of hospitalization, while improving sleep quality could significantly reduce the length of hospital and intensive care unit stays (9). In addition, poor sleep quality combined with chronic retinal stimulation by electronic devices and extended or night work shifts, may worsen lung inflammation and aggravate the symptoms of COVID-19 infection (10). Furthermore, poor sleep quality can trigger oxidative stress and antioxidant imbalances and induce health-damaging pro-inflammatory states. To reduce the harmful effects of poor sleep quality on COVID-19 patients and allocate appropriate health resources, it is important to understand its pattern and associated factors (4, 11).

During the past years, prevalence studies of poor sleep quality in COVID-19 patients found wide variations, ranging from 25.5 to 88.6% (12–14), which is probably related to differences in COVID-19 severity and stages (e.g., COVID-19 onset, recovery, acute post-symptom onset), comorbidities, treatment regimens, and measures on sleep quality and cut-off values (15–19). There are various systematic reviews and meta-analyses that focused on the management of COVID-19, such as the role of methylprednisolone (20), aspirin (21), and baricitinib (22) in COVID-19 patients, but no meta-analysis on the prevalence of poor sleep quality in COVID-19 patients has been published. Therefore, we conducted this meta-analysis on the global prevalence of poor sleep quality in COVID-19 patients and its associated factors.

2 Methods

2.1 Search strategy

This meta-analysis was conducted based on the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) (23) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) recommendations (24). The protocol was registered in the International Platform of Registered Systematic Review and Metaanalysis Protocols (INPLASY), with the registration number of INPLASY202320121. Three researchers (ZG, YY-W, and JX-L) independently retrieved relevant literature in PubMed, Web of Science, Embase, and PsycINFO databases from their inception until October 27, 2022, with the following search terms: (SARS-CoV-2 [MeSH] OR SARS Coronavirus 2 OR Coronavirus 2, SARS OR Coronavirus Disease 2019 Virus OR 2019 Novel Coronavirus OR 2019 Novel Coronaviruses OR Coronavirus, 2019 Novel OR Novel Coronavirus, 2019 OR SARS-CoV-2 Virus OR SARS CoV 2 Virus OR SARS-CoV-2 Viruses OR Virus, SARS-CoV-2 OR 2019-nCoV OR COVID-19 Virus OR COVID 19 Virus OR COVID-19 Viruses OR Virus, COVID-19 OR COVID19 Virus OR COVID19 Viruses OR Virus, COVID19 OR Viruses, COVID19 OR 2019 novel coronavirus infection OR COVID19 OR coronavirus disease 2019 OR coronavirus disease-19 OR 2019-nCoV disease OR 2019 novel coronavirus disease OR 2019-nCoV infection OR COVID-19 patients OR COVID-19 patient OR COVID-19 survivor) AND (Sleep Quality [MeSH] OR Qualities, Sleep OR Quality, Sleep OR Sleep Qualities OR quality of sleep OR sleeping quality OR Pittsburgh sleep quality index OR PSQI).

2.2 Study selection

The same researchers independently screened the titles and abstracts of all relevant publications, and then read the full texts to determine eligibility. Any disagreement was resolved by consensus among the three researchers or by discussion with a senior researcher (YT-X). Supplementary Figure S1 shows the detailed process of the literature search. The inclusion criteria for this study were based on the PICOS acronym (25): Participants (P): COVID-19 patients based on positive Coronavirus RT-PCR (reverse transcription-polymerase chain reaction) of nasopharyngeal and oropharyngeal swabs or a history of COVID-19 infection. Following previous research (26, 27), the COVID-19 patients in this study included the period of COVID-19 infection, symptom onset, recovery, and the onset of post-acute COVID-19 symptoms. Interventions (I): not applicable; Comparisons (C): healthy controls in comparative studies, or not applicable to epidemiological surveys; Outcome (O): the prevalence of poor sleep quality or available data could yield the prevalence of poor sleep quality in COVID-19 patients. Sleep quality in COVID-19 patients was assessed using any standardized scales such as the PSQI (7, 28); Study design (S): epidemiological and comparative studies (only the baseline data of cohort study were extracted). Exclusion criteria were as follows: (1) published in non-English language; (2) studies that only used individual items rather than the full version of a standardized scales on sleep quality; (3) patients with sleep-related disorders (as recommended in a previous meta-analysis) (29). If a dataset was used in multiple papers, only the paper with the complete information was included in this meta-analysis.

2.3 Data extraction and quality assessment

The same researchers independently extracted relevant information from the included studies and recorded them using an Excel data collection spreadsheet. The following information was extracted: study characteristics [e.g., title, journal, first author, publication year, study site by country, survey time, study design, assessment method, day zero (26), sampling method, cut-off value of standard scales on sleep quality, study quality score, and comorbidities associated with sleep quality], characteristics of COVID-19 patients [e.g., number of COVID-19 patients, number with poor sleep quality, total scores of standard scales on sleep quality, mean age (year), proportion of males, proportion of married status, proportion of smoking patients, average days of hospitalization, proportion of ICU admission, prevalence of anxiety and depression, and component scores of standard scales on sleep quality (i.e., subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medications, daytime dysfunction in the PSQI)] and characteristics of healthy controls [e.g., number of healthy controls, number of poor sleep quality, total scores of standard scales on sleep quality, mean age (year), and proportion of males].

For epidemiological studies, study quality was assessed using an eight-item assessment instrument with a scale of 0–8 (30), with scores of 0–3, 4–6, and 7–8 were considered "low quality", "moderate quality", and "high quality," respectively (31). Study quality of comparative studies was assessed using the Newcastle-Ottawa Scale (NOS) (32). The NOS included eight items in three categories. In addition to the maximum of 2 stars for comparability, the remaining items could be rated up to 1 star, with a full score of 9 stars. Therefore, the NOS total score in this study ranges from 1 to 9 points, with a higher score indicating higher quality. Details of the study quality assessment tools are shown in Supplementary Table S1.

2.4 Statistical analysis

All data analyses were performed using R software (version 4.2.2¹) with the "meta" package (33). The random-effects model was used to estimate the pooled prevalence of poor sleep quality with the corresponding 95% confidence intervals (95% CIs). The I² statistic was used to assess the heterogeneity of the study, with I² greater than 50% indicating high heterogeneity (34). Subgroup analyses were performed based on the following categorical variables if there were at least 3 studies in each subgroup (35): cut-off values of standard scales on sleep quality, income levels by country (i.e., High income, vs. upper middle income, vs. lower middle income) according to the World Bank standard,² assessment method (e.g., online survey vs. face-toface interview), day zero (e.g., symptom onset vs. hospital discharge vs. hospital admission of COVID-19 patients), study design, gender, and sampling method. If there were at least 10 studies (36), metaregression analyses were performed for the following continuous variable: sample size, mean age (year), proportion of males, proportion of married status, proportion of smoking patients, average days of hospitalization, proportion of ICU admission, quality score, and the prevalence of anxiety and depression. Funnel plot and Egger's test were used to examine the publication bias. Sensitivity analysis examined the consistency of preliminary results by excluding studies one by one. Significant level was set at p < 0.05 (two-tailed).

3 Results

3.1 Search results and study characteristics

A total of 4,238 relevant publications were initially searched and finally, 36 studies met the study entry criteria and were included in

this meta-analysis, of which there were 24 epidemiological and 12 comparative studies (Supplementary Figure S1). After reading the titles and abstracts initially, 293 articles were screened for eligibility by reading the full text, of which, 256 articles were excluded. The reasons for exclusion are outlined in Supplementary Table S2.

A total of 8,146 COVID-19 patients and 5,787 healthy controls were included in this study and their basic characteristics are shown in Table 1. The age range of the participants were between 18 and 99 years. The most number of studies were conducted in Turkey (6 studies, 16.7%), followed by China (5 studies, 13.9%) and Spain (4 studies, 11.1%). Most of the included studies were cross-sectional (26 studies, 72.2%), followed by cohort studies (6 studies, 19.4%). All studies used the PSQI as the measure on sleep quality; 16 studies used the PSQI cut-off values of ≥ 6 (44.4%), while 14 studies used the cut-off values of \geq 5 (38.9%) and 6 studies used the cut-off values of \geq 8 (16.7%). Twenty-one studies reported comorbid anxiety and depression, respectively. The study quality assessment scores of 24 epidemiological studies ranged from 4 to 7, of which only 1 study was rated as "high quality," and the remaining 23 studies (95.8%) were rated as "moderate quality." In addition, quality assessment scores of the 12 comparative studies ranged from 4 to 6, with a mean score of 5.1 (SD: 0.8) (Supplementary Table S1).

3.2 Pooled prevalence of poor sleep quality, PSQI global and component score in COVID-19 patients

The pooled prevalence of poor sleep quality based on all 36 studies was 65.0% (95%CI: 59.56–70.44%, I^2 =97.6%) (Figure 1). Table 2 shows that a total of 21 studies with 5,999 COVID-19 patients reported on the total PSQI score, with a pooled total PSQI score of 7.44 (95% CI: 6.82–8.05, I^2 =94.2%). In addition, 6 studies with 1,014 COVID-19 patients reported on the sleep component scores in seven domains, with pooled data ranging from 0.53 (95% CI: 0.26–0.79, I^2 =90.2%) for "use of sleep medications" to 1.50 (95% CI: 1.28–1.73, I^2 =89.2%) for "sleep latency."

3.3 Odds ratio for poor sleep quality between COVID-19 patients and healthy controls

The Odds Ratio (OR) of the 12 comparative studies on the prevalence of poor sleep quality between COVID-19 patients and healthy controls is shown in Figure 2. Specifically, COVID-19 patients had a higher risk of poor sleep quality compared to healthy controls (OR=1.73, 95% CI: 1.30–2.30, p < 0.01, $I^2 = 78.1\%$). Moreover, COVID-19 patients had significantly higher PSQI total scores than healthy controls, with a large effect size (SMD=0.31, 95%CI: 0.07–0.55, p < 0.0001, $I^2 = 92\%$) (Supplementary Figure S3).

3.4 Subgroup and meta-regression analyses

The results of subgroup analysis showed that the cut-offs of PSQI (p < 0.001) and countries by income (p = 0.011) were significantly

¹ https://www.r-project.org

² https://www.worldbank.org

TABLE 1 Basic characteristics of studies included in this meta-analysis.

Ν	No. First author, Study site Survey Study Assessment Day zero						t Day zero	Sampling	PSQI	COVID-19 patients											Healthy control Qua					Quality
	yea	olication ar	(Country)	time	design	method		metnod	off	No. of COVID-19 patients (n)	No. of PSQ	PSQI total score (mean)	Mean age (years)	Male (%)	Married (%)	Smoking (%)	Average days at hospitalization	ICU admission (%)	Anxiety (%)	Depression (%)	No. of healthy controls (n)	No. of PSQ	PSQI total score (mean)	Mean age (years)	Male (%)	score
1	Abb	as et al. (37)	Kuwait	May–July 2020	Cross-sectional	Online survey	Symptom onset	NR	≥6	7	6	NR	NR	NR	NR	NR	NR	NR	NR	NR	210	165	NR	NR	NR	5
2	Abd (38)	elghani et al.	Egypt	September– November 2020	Cross-sectional	Clinic interviev	v Hospital discharge	С	≥5	85	65	NR	36.0	18.8	88.2	NR	NR	NR	25	29	85	39	NR	33.7	27.1	6
3	Ahn	ned et al. (12)	Egypt	January -Mach 2021	Cross-sectional	Clinic follow up	Hospital discharge	NR	≥5	182	118	NR	46.5	46.2	70.3	30.8	12.2	NR	28	12	NR	NR	NR	NR	NR	4
4	Akir	nci et al. (9)	Turkey	April–May 2020	Cross-sectional	Hospital survey	Hospital	NR	≥5	189	102	NR	46.3	59.0	82.5	NR	7.3	NR	13	43	NR	NR	NR	NR	NR	6
5	Ako	va et al. (39)	Turkey	March– April 2021	Cross-sectional	Clinic interviev	v Hospital discharge	NR	≥5	133	79	5.7	36.0	45.1	67.7	26.3	NR	NR	NR	NR	NR	NR	NR	NR	NR	5
6	Al-A (40)	Ameri et al.	all Arabic nations	January– March 2021	Case-control	Online survey	Hospital discharge	NR	≥6	256	215	8.8	37.1	NR	NR	NR	NR	5.1	NR	NR	491	384	8.1	36.2	NR	6
7	Al-C (41)	Dtaibi et al.	Kuwait	August 2020–April 2021	Cross-sectional	Online survey	Symptom onset	R	≥6	13	10	NR	NR	NR	NR	NR	NR	NR	62	NR	93	59	NR	NR	NR	4
8	Alsh (17)	umrani et al.	Saudi Arabia	May– September 2020	Cross-sectional	Online survey	Symptom onset	t C	≥6	643	425	6.9	42.8	61.6	NR	NR	NR	NR	NR	40	448	326	7.6	37.3	52.0	4
9	Am	ra et al. (13)	Iran	May–June 2020	Cross-sectional	NR	Hospital discharge	NR	≥5	35	31	9.0	34.4	28.6	77.1	NR	NR	NR	57	63	337	261	6.9	34.5	34.7	5
1	0 Awa	n et al. (42)	Pakistan	April– September 2021	Cross-sectional	Hospital follow up	Hospital discharge	NR	≥6	50	32	NR	49.6	52.0	66.0	NR	NR	NR	24	10	NR	NR	NR	NR	NR	4
1	1 Beni	itez et al. (43)	Spain	March 2020–April 2021	Cohort	Clinic interviev	v ICU discharge	С	≥6	172	104	7.1	60.5	67.4	NR	45.9	24.6	100	25	15	NR	NR	NR	NR	NR	4
1:	2 Bun (44)	genberg et al.	Germany	August 2020– March 2021	Longitudinal prospective	Interview	Symptom onset	NR	≥6	36	31	9.3	NR	NR	NR	26.0	NR	NR	NR	NR	NR	NR	NR	NR	NR	4
1	3 Caco (45)	ciatore et al.	Italy	February– April 2020	Cohort	Clinic interviev	v Hospital discharge	NR	≥5	83	62	6.5	66.9	75.9	NR	NR	13.0	NR	15	16	NR	NR	NR	NR	NR	5
1	4 Chh (71)	ajer et al.	India	June 2021	Cross-sectional	Online survey	Hospital discharge	Р	≥5	311	245	8.2	NR	39.5	49.8	NR	NR	NR	31	38	NR	NR	NR	NR	NR	4
1	5 Cho (46)	udhry et al.	Pakistan	January– March 2021	Longitudinal	NR	Symptom onset	C	≥5	445	201	6.3	42.0	65.3	NR	22.6	4.0	100	NR	NR	NR	NR	NR	NR	NR	6

(Continued)

TABLE 1 (Continued)	TABLE 1	(Continued)
---------------------	---------	-------------

No.	First author,	Study site	Survey	Study	Assessment	Day zero	Sampling	PSQI						COVID	-19 patier	nts					Healt	hy contr	ol		Quality
	year	(Country)		ucsign	inethou		method	off	No. of COVID-19 patients (n)	No. of PSQ	PSQI total score (mean)	Mean age (years)	Male (%)	Married (%)	Smoking (%)	Average days at hospitalization	ICU admission (%)	Anxiety (%)	Depression (%)	No. of healthy controls (n)	No. of PSQ	PSQI total score (mean)	Mean age (years)	Male (%)	30010
16	Dai et al. (47)	China	February 2020	Cross-sectional	Online survey	Hospital admission	NR	≥6	307	260	NR	NR	56.7	81.8	21.8	NR	NR	19	13	NR	NR	NR	NR	NR	5
17	Del Brutto et al. (83)	Ecuador	May–June 2020	Longitudinal prospective	Face-to-face interview	Hospital discharge	NR	≥6	325	184	NR	NR	NR	NR	NR	NR	NR	NR	NR	314	127	NR	NR	NR	6
18	Delgado-Alonso et al. (19)	Spain	NR	Cross-sectional	NR	Post-acute COVID-19 syndrome	NR	≥6	50	40	10.1	51.1	26.0	NR	8.0	19.1	10.0	52	30	NR	NR	NR	NR	NR	5
19	ElHafeez et al. (48)	Egypt	April–June 2020	Cross-sectional	Online survey	Hospital discharge	С	≥6	25	19	NR	NR	NR	NR	NR	NR	NR	NR	NR	975	665	NR	NR	NR	6
20	Fernandez et al. (5)	Spain	January– February 2021; July– August 2021	Cohort	Telephone interview	Hospital discharge	NR	≥8	164	69	5.6	60.7	42.1	NR	NR	16.9	17.7	1	8	NR	NR	NR	NR	NR	4
21	Fernandez et al. (5)	Spain	March– June 2020	Cohort	Telephone interview	Hospital discharge	R	≥8	1969	674	6.5	61.1	52.7	NR	NR	11.2	6.5	15	19	NR	NR	NR	NR	NR	7
22	Gundogdu et al. (49)	Turkey	August 2020– March 2021	Cross-sectional	Clinic interview	Hospital discharge	NR	≥5	83	47	NR	57.0	59.0	NR	36.0	15.3	30.1	NR	NR	NR	NR	NR	NR	NR	5
23	Gunes et al. (50)	Turkey	May–June 2020	Cross-sectional	Interview	Hospital admission	NR	≥6	49	27	6.1	46.0	55.1	89.8	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	4
24	Hartung et al. (51)	Germany	November 2020– September 2021	Prospective multicenter	Clinic interview	Hospital discharge	R	≥5	634	513	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	6
25	Henriquez et al. (52)	Chile	April–July 2020	Cross-sectional	Questionnaire survey	Hospital discharge	NR	≥6	60	52	9.9	46.3	53.3	NR	46.7	NR	NR	23	10	NR	NR	NR	NR	NR	4
26	Karaogullarindan et al. (53)	Turkey	February– March 2021	Cross-sectional	Questionnaire survey	Hospital admission	NR	≥5	71	38	6.6	60.0	57.7	NR	NR	NR	NR	66	63	71	23	4.8	53.5	57.7	4
27	Li, X. et al. (14)	China	February– March 2020	Cross-sectional	Online survey	Diagnosis date	NR	≥8	51	13	NR	NR	42.4	86.4	18.0	NR	NR	23	28	NR	NR	NR	NR	NR	6
28	Li, Z. et al. (18)	China	April–May 2021	Cross-sectional	Questionnaire survey	Hospital discharge	NR	≥6	535	252	6.2	50.8	40.4	NR	12.1	NR	NR	16	21	NR	NR	NR	NR	NR	6
29	Lin et al. (54)	China	February 2020	Cross-sectional	Online survey	Hospital discharge	NR	≥8	29	11	NR	NR	NR	NR	NR	NR	NR	NR	NR	1868	558	NR	NR	NR	6
																								(Co	ntinued)

Frontiers in Psychiatry

TABLE 1 (Continued)

No. First author, Study site Survey Study Assessment Day zero Sampling PSQI COVID-19 patients Healthy co								hy cont	rol	Quality															
l	Publication year	(Country)	time	design	metnoa		method	off	No. of COVID-19 patients (n)	No. of PSQ	PSQI total score (mean)	Mean age (years)	Male (%)	Married (%)	Smoking (%)	Average days at hospitalization	ICU admission (%)	Anxiety (%)	Depression (%)	No. of healthy controls (n)	No. of PSQ	PSQI total score (mean)	Mean age (years)	Male (%)	score
30	Malik et al. (55)	Pakistan	April– September 2020	Cross-sectional	Online survey	Diagnosis date	R	≥6	296	182	7.0	NR	38.2	NR	NR	NR	NR	NR	NR	301	146	5.8	NR	43.9	5
31	Nowakowski et al. (56)	USA	August 2020– September 2021	Cohort	Clinic interview or 1 h long telehealth	Hospital discharge	С	≥5	79	65	9.7	48.2	30.4	NR	NR	NR	11.4	38	47	NR	NR	NR	NR	NR	4
32	Rousseau et al. (15)	Belgium	March–July 2020	Cohort	Face-to-face follow up	ICU discharge	NR	≥5	32	24	6.8	60.3	71.9	NR	NR	40.3	100	25	13	NR	NR	NR	NR	NR	5
33	Sljivo et al. (57)	Bosnia, Herzegovina, Croatia, Serbia	February– , August 2021	Cross-sectional	Online survey	Symptom onset	NR	≥5	464	362	7.0	NR	18.1	34.3	NR	NR	NR	NR	NR	594	362	5.4	NR	19.0	5
34	Tanriverdi et al. (58)	Turkey	January– February 2021	Cross-sectional	NR	Hospital discharge	NR	≥6	48	24	6.1	39.2	45.8	72.9	6.3	NR	NR	33	29	NR	NR	NR	NR	NR	4
35	Yadav et al. (61)	India	June– August 2020	Cross-sectional	Hospital survey	Diagnosis date	NR	≥8	100	62	8.8	42.9	73.0	NR	33.0	NR	NR	67	27	NR	NR	NR	NR	NR	5
36	Zhang J et al. (16)) China	January– March 2020	Cohort	Hospital survey	Hospital discharge	NR	≥8	135	75	9.0	63.0	57.8	95.6	3.0	31.3	6.7	NR	NR	NR	NR	NR	NR	NR	5

-

06

ICU, Intensive Care Unit; PSQI, Pittsburgh Sleep Quality Index; NR, not reported; C, Convenient; R, Random; P, Purposive; No. of PSQ, Number of poor sleep quality participants.

Study	Events	Total		Proportion	95%-CI	Weight
Abbas et al. 2021	6	7		0.86	[0.42; 1.00]	1.8%
Abdelghani et al. 2022	65	85		0.76	[0.66; 0.85]	2.8%
Ahmed et al. 2021	118	182	— <u>—</u> —	0.65	[0.57; 0.72]	2.9%
Akinci et al. 2021	102	189		0.54	[0.47; 0.61]	2.9%
Akova et al. 2022	79	133		0.59	[0.51; 0.68]	2.9%
Al-Ameri et al. 2022	215	256	÷	0.84	[0.79; 0.88]	3.0%
Al-Otaibi et al. 2022	10	13		0.77	[0.46; 0.95]	2.0%
Alshumrani et al. 2022	425	643		0.66	[0.62; 0.70]	3.0%
Amra et al. 2021	31	35	· · · · · · · · · · · · · · · · · · ·	0.89	[0.73; 0.97]	2.8%
Awan et al. 2022	32	50		0.64	[0.49; 0.77]	2.6%
Benitez et al. 2022	104	172		0.60	[0.53; 0.68]	2.9%
Bungenberg et al. 2022	31	36		0.86	[0.71; 0.95]	2.7%
Cacciatore et al. 2022	62	83	÷ 🗖	0.75	[0.64; 0.84]	2.8%
Chhajer et al. 2022	245	311		0.79	[0.74; 0.83]	3.0%
Choudhry et al. 2021	201	445		0.45	[0.40; 0.50]	3.0%
Dai et al. 2020	260	307		0.85	[0.80; 0.89]	3.0%
Del Brutto et al. 2021	184	325		0.57	[0.51; 0.62]	3.0%
Delgado-Alonso et al. 2022	40	50		0.80	[0.66; 0.90]	2.7%
ElHafeez et al. 2022	19	25		0.76	[0.55; 0.91]	2.4%
Fernandez et al. 2022	69	164	· · · · · · · _	0.42	[0.34; 0.50]	2.9%
Fernandez et al. 2022	674	1969		0.34	[0.32; 0.36]	3.1%
Gundogdu et al. 2022	47	83		0.57	[0.45: 0.67]	2.8%
Gunes et al. 2022	27	49		0.55	[0.40; 0.69]	2.6%
Hartung et al. 2022	513	634		0.81	[0.78; 0.84]	3.1%
Henriquez et al. 2022	52	60		0.87	[0.75: 0.94]	2.9%
Karaogullarindan et al. 2021	38	71	<u></u>	0.54	[0.41: 0.65]	2.7%
Li, X, et al. 2021	13	51	·	0.25	[0.14: 0.40]	2.7%
Li, Z, et al. 2022	252	535		0.47	[0.43: 0.51]	3.0%
Lin et al. 2022	11	29	İ	0.38	[0.21: 0.58]	2.3%
Malik et al. 2022	182	296	·	0.61	[0.56: 0.67]	3.0%
Nowakowski et al. 2022	65	79		0.82	[0.72: 0.90]	2.9%
Rousseau et al. 2021	24	32		0.75	[0.57: 0.89]	2.5%
Sliivo et al. 2022	362	464		0.78	[0.74: 0.82]	3.0%
Tanriverdi et al. 2022	24	48		0.50	[0.35: 0.65]	2.5%
Yaday et al 2021	62	100		0.62	[0.52, 0.72]	2.8%
Zhang et al 2020	75	135		0.56	[0.02, 0.72]	2.0%
	75	100		0.00	[0.47, 0.04]	2.370
Random effects model		8146		0.65	[0.60; 0.70]	100.0%
Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0$)250, p < 0	.01				
			0.2 0.4 0.6 0.8			
FIGURE 1						
Meta-analysis of prevalence of poor	sleep quali	ity in CO	DVID-19 patients.			

associated with the prevalence of poor sleep quality in COVID-19 patients. COVID-19 patients in lower middle-income countries were more likely to have poor sleep quality than those in upper middle income and high-income countries (64.9% vs. 60.1% vs. 55.8%). Metaregression analyses of 24 epidemiological studies revealed that mean age (β =1.0000, *z*=42.6046, *p*<0.001) and married status (β =0.0016, *z*=2.6261, *p*=0.009) were positively correlated with the prevalence of poor sleep quality in COVID-19 patients, while proportion of males (β =-0.0003, *z*=-2.0108, *p*=0.044) and quality score (β =-0.0873, *z*=-2.4469, *p*=0.014) were negatively correlated with the prevalence of poor sleep quality in COVID-19 patients (Table 3).

3.5 Publication bias and sensitivity analyses

As shown in Supplementary Figures S2A,B, no publication bias was found in funnel plots. The Egger tests of the 36 studies (t=1.41, p=0.168) and the 12 comparative studies (t=0.77, p=0.457) also did not find any publication bias. Moreover, Supplementary Figures S4, S5 display the sensitivity analyses for the prevalence of poor sleep quality

in the 36 studies and also the odds ratio in the 12 comparative studies, respectively. No outlying studies were found that could significantly alter the primary results.

4 Discussion

This is the first meta-analysis of the pooled prevalence of poor sleep quality in COVID-19 patients. The results showed that 65.0% (95%CI: 59.56–70.44%) of COVID-19 patients had poor sleep quality, which was around two times higher than that in healthy controls (OR = 1.73, 95%CI: 1.30–2.30). Globally, there were more than 757 million COVID-19 confirmed cases (59), which means that approximately 492 million COVID-19 patients suffered from poor sleep quality based on the prevalence rate found in this study. The COVID-19 pandemic had a profound impact on sleep quality in the population especially COVID-19 patients (11). A meta-analysis found that sleep problems were common and strongly associated with higher levels of psychological distress among health professionals, the general population, and COVID-19 patients during the COVID-19 pandemic TABLE 2 The pooled PSQI global and sleep component scores in COVID-19 patients.

Variables	Number of studies	Sample size	Pooled mean score (95% CI)	l ²	p values
PSQI global score	21	5,999	7.44 (6.82-8.05)	94.2%	< 0.001
Subjective sleep quality	6	1,014	1.37 (1.12–1.63)	94.6%	< 0.001
Sleep latency	6	1,014	1.50 (1.28–1.73)	89.2%	< 0.001
Sleep duration	6	1,014	1.12 (0.89–1.36)	92.4%	< 0.001
Habitual sleep efficiency	6	1,014	0.84 (0.65–1.02)	84.1%	< 0.001
Sleep disturbance	6	1,014	1.32 (1.15–1.50)	93.0%	< 0.001
Use of sleep medications	6	1,014	0.53 (0.26-0.79)	90.2%	< 0.001
Daytime dysfunction	6	1,014	1.10 (0.88–1.32)	92.6%	< 0.001

CI, confidence interval; PSQI, Pittsburgh Sleep Quality Index.

	Experir	nentl	He con	althy trols				
Study	Events	Total	Events	Total	Odds Ratio	OR	95%-CI	Weight
Abbas et al. 2021	6	7	165	210		1.64	[0.19; 13.94]	1.6%
Abdelghani et al. 2022	65	85	39	85		3.83	[1.98; 7.40]	8.2%
Al-Ameri et al. 2022	215	256	384	491		1.46	[0.98; 2.17]	11.3%
Al-Otaibi et al. 2022	10	13	59	93		1.92	[0.49; 7.47]	3.4%
Alshumrani et al. 2022	425	643	326	448		0.73	[0.56; 0.95]	12.8%
Amra et al. 2021	31	35	261	337		2.26	[0.77; 6.59]	4.8%
Del Brutto et al. 2021	184	325	127	314		1.92	[1.40; 2.63]	12.3%
ElHafeez et al. 2022	19	25	665	975		1.48	[0.58; 3.73]	5.7%
Karaogullarindan et al. 2021	38	71	23	71		2.40	[1.22; 4.75]	7.9%
_in et al. 2022	11	29	558	1868		1.43	[0.67; 3.06]	7.2%
Malik et al. 2022	182	296	146	301		1.69	[1.22; 2.35]	12.1%
Sljivo et al. 2022	362	464	362	594		2.27	[1.73; 2.99]	12.7%
Random effects model		2249		5787		1.73	[1.30; 2.30]	100.0%
Heterogeneity: $I^2 = 78\%$, $\tau^2 = 0.14$	495, p < 0	0.01						
					0.1 0.5 1 2 10			
125.0								
JRE Z								

(60). Another meta-analysis showed that sleep disturbances including poor sleep quality were higher among COVID-19 patients during lockdown periods compared with periods without lockdowns, and COVID-19 patients were the most affected subgroup (7). The high rate of sleep disturbances including poor sleep quality in COVID-19 patients may be related to several factors. First, sleep problems, including poor sleep quality, are among the main symptoms of COVID-19 infection (11). During the COVID-19 pandemic, the risk of mental health problems such as depression and anxiety increased, which had a negative impact on sleep quality of COVID-19 patients (27, 61). Second, those infected with COVID-19 are more likely to experience physical health problems (1, 2), such as fever, headache, dyspnea, myalgia, throat pain, cough, gastrointestinal disturbance, and other COVID-19 related symptoms (5, 6), which can affect immunological response and compromise sleep quality by altering related circadian rhythms (62). Moreover, many COVID-19 patients may suffer from impaired lung function and various sleep-related problems, such as obstructive sleep apnea, which affected sleep quality (63, 64). Third, usually COVID-19 patients are placed in long-term isolation treatment and tend to overuse their electronic devices during isolation causing chronic retinal irritation, which may lead to disturbance in sleep and circadian rhythm, and eventually poor sleep quality (65, 66). In addition, the strict lockdown measures can influence normal rhythms of the sleep–wake cycle among COVID-19 patients by reducing social activities and supports, increasing time spent in bed and delaying bedtimes (67, 68). As a result, depression, anxiety and insomnia are more likely to occur, thereby lowering their sleep quality (69, 70).

Subgroup analyses revealed that the prevalence of poor sleep quality in COVID-19 patients was higher in studies using PSQI cut-off value of 6 (69.5, 95% CI: 62.5-76.2%) compared to those using other PSQI cut-off values (e.g., cut-off of 8: 43.1, 95% CI: 32.2-54.1%), which is unsurprising given that a more stringent criterion for poor sleep quality would be associated with a lower prevalence rate. Poor sleep quality in COVID-19 patients in lower income countries (64.9, 95% CI: 62.6-67.2%) was more common than in higher income countries (e.g., upper middle income: 60.1, 95% CI: 58.1-62.2%; high income: 55.8, 95% CI: 55.4-57.2%), which could be explained by the fact that COVID-19 patients in low-income countries have less access to adequate and high-quality medical services compared to highincome countries (71). COVID-19 patients in high-income countries with advanced health system and greater resources tend to receive better care (72, 73) and have a lower mortality rate, which may also result in a lower risk of mental health problems such as anxiety, depression and insomnia among COVID-19 patients (72, 74, 75). In addition, both subgroup and meta-regression analyses revealed that

	Subgroup analysis													
Subgroups	No. of studies	No. of studies	Sample size	Having poor sleep quality	Proportion (95% CI)	l²(%)	<i>p</i> -value within subgroups	p-value across subgroups						
Cut-offs of PSQI	≥5	14	2,826	1,952	69.2 (62.1; 76.2)	94.8	<0.01	<0.001						
	≥6	16	2,872	1,863	69.5 (62.5; 76.5)	94.7	<0.01							
	≥8	6	2,448	904	43.1 (32.2; 54.1)	91.3	<0.01							
Countries by income	High income	13	3,942	2,075	55.8 (55.4; 57.2)	98.6	<0.01	0.011						
	Upper middle income	12	1,955	1,112	60.1 (58.1; 62.2)	95.2	<0.01							
	Lower middle income	9	1,529	955	64.9 (62.6; 67.2)	94.1	<0.01							
Assessment method	Online survey	11	2,402	1,748	74.7 (73.0; 76.4)	94.2	<0.01	0.474						
	Interview	16	4,265	2,196	54.1 (52.7; 55.4)	98.1	< 0.01							
Day zero	Symptom onset	6	1,608	1,035	71.5 (58.1; 84.8)	96.2	<0.01	0.642						
	Hospital discharge	22	5,425	2,960	65.2 (58.3; 72.1)	98.1	<0.01							
	Hospital admission	4	616	427	62.5 (46.7; 78.3)	96.1	<0.01							
Study design	Cross-sectional	26	4,016	2,602	65.2 (58.8; 71.6)	94.0	<0.01	0.806						
	Cohort	6	2,470	1,004	63.2 (48.7; 77.7)	97.9	<0.01							
Gender	male	4	465	218	46.9 (42.3; 51.4)	0.0	0.53	0.025						
	female	4	527	290	60.1 (49.4; 70.8)	83.8	<0.01							
Sampling method	Convenient	6	1,449	879	67.1 (55.9; 78.3)	94.5	< 0.01	0.713						
	Random	4	2,912	1,379	62.6 (41.1; 84.0)	99.5	<0.01							
		Meta	-regression An	alysis in 24 epidemi	ological studies									
Variables	Number of	Coef	ficient	Standard	95% lower	95%	Z-value	p-value						
	studies			error		Upper								
Sample size	24	-0.	.0001	0.0002	-0.0006	0.0003	-0.5559	0.578						
Mean age (year)	16	1.0	0000	0.0235	0.9540	1.0460	42.6046	<0.001						
Male gender, %	22	-0.	.0003	0.0002	-0.0006	-0.0000	-2.0108	0.044						
Married, %	10	0.0	0016	0.0006	0.0004	0.0027	2.6261	0.009						
Smoking, %	13	-0.	.0001	0.0016	-0.0032	0.0031	-0.0357	0.972						
Days at hospitalization (days)	11	0.0	0055	0.0060	-0.0062	0.0172	0.9275	0.354						
ICU admission, %	ion, % 9 0.0124		0124	0.1495	-0.2807	0.3055	0.0828	0.934						
Anxiety, %	17	0.4	4021	0.2916	-0.1695	0.9736	1.3788	0.168						
Depression, %	17	-0.	2669	0.2554	-0.7674	0.2337	-1.0449	0.296						
Quality score	24	-0.	.0873	0.0357	-0.1572	-0.0174	-2.4469	0.014						

TABLE 3 Subgroup and meta-regression analyses of prevalence of poor sleep quality in COVID-19 patients.

CI, confidence interval; ICU, Intensive Care Unit; PSQI, Pittsburgh Sleep Quality Index. Bold values: *p* < 0.05.

women had a higher risk of poor sleep quality than men. This is consistent with previous findings that women are more likely to experience sleep problems than men such as poorer sleep quality, longer sleep latency periods, and more frequent use of sedative and hypnotic drugs (76). In addition, some studies found that women had more severe sleep difficulties than men during the COVID-19 pandemic due to shorter sleep duration and longer sleep latency (77, 78). This might be related to the finding that women are more susceptible than men to stress-related conditions (79, 80). A study conducted in Mexico found that the COVID-19 pandemic had different influences on women and men; for example, females reported more severe psychological distress, stress, and poorer sleep quality than males, probably related to the gender differences in response to stress, sensitivity to life events, and domestic and childcare responsibilities (81, 82).

Meta-regression analysis found more common poor sleep quality in older COVID-19 patients, which is consistent with previous research (83). There could be several reasons for this finding, first, older COVID-19 patients may have less outdoor activities and physical exercise, and spend more time in bed, leading to an increased risk of physical and psychological problems (84–86). Second, severe infection and morbidity rate are more common in older COVID-19 patients (87). Third, the likelihood of poor sleep quality and reduced sleep duration also increase with age. Meta-regression analysis also found that married COVID-19 patients had a higher risk of poor sleep quality. Compared to their unmarried counterparts, married COVID-19 patients may experience greater psychological pressure due to the fear of transmitting the virus to their family members, particularly children. Finally, higher quality studies were associated with a lower prevalence of poor sleep quality in COVID-19 patients. Stricter study design and more reliable measures were usually adopted in higher quality studies, which could reduce the likelihood of false positive rate and result in a lower prevalence of poor sleep quality.

The strengths of this meta-analysis included the large number of studies across different countries, inclusion of both epidemiological and comparative studies, and the use of sophisticated analyses such as subgroup, meta-regression, and sensitivity analyses. Additionally, all studies had used the PSQI to measure sleep quality, which would reduce the heterogeneity caused by different tools. However, several limitations of this study should be considered. First, due to the limited data, some factors related to sleep quality of COVID-19 patients could not be examined such as patients' physical comorbidities, illness severity and treatment of COVID-19 patients. Second, due to differences in demographic data, COVID-19 related variables, sampling method and scale cutoff values between studies, heterogeneity could not be avoided in meta-analyses of epidemiological studies (88-91), even though subgroup analyses and meta-regression analyses were performed (92, 93). Finally, only published articles in English were included in this meta-analysis, which may bias the results of this study to an uncertain extent.

In conclusion, poor sleep quality was found to be very common in COVID-19 patients, especially in low-income countries, females, older adults and married patients. Considering the negative effects of poor sleep quality on daily life, sleep quality of COVID-19 patients should be assessed regularly, and effective treatments should be provided.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

ZG: Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Writing

References

1. Lee JH, Lee D, Hyun S, Hong JS, Kim CH, Kim W, et al. Online mental health assessments of COVID-19 patients in South Korea. *Front Psych.* (2021) 12:8. doi: 10.3389/fpsyt.2021.685445

2. Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, et al. Predicting disease severity and outcome in COVID-19 patients. *Arch Pathol Lab Med.* (2020) 144:1465–74. doi: 10.5858/arpa.2020-0471-SA

3. Caroppo E, Mazza M, Sannella A, Marano G, Avallone C, Claro AE, et al. Will nothing be the same again?: Changes in lifestyle during COVID-19 pandemic and consequences on mental health. *Int J Environ Res Public Health*. (2021) 18:8433. doi: 10.3390/ijerph18168433

4. Kumar N, Gupta R. Disrupted sleep during a pandemic. Sleep Med Clin. (2022) 17:41–52. doi: 10.1016/j.jsmc.2021.10.006

original draft. Y-YW: Data curation, Writing – review & editing.
J-XL: Data curation, Writing – review & editing. X-HL: Data curation, Writing – review & editing. ZS: Data curation, Writing – review & editing. K-IL: Data curation, Writing – review & editing. GU: Data curation, Writing – review & editing. CN: Data curation, Writing – review & editing, Mriting – review & editing. QZ: Writing – review & editing, Methodology. Y-TX: Data curation, Formal Analysis, Investigation, Methodology, Project administration, Software, Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was supported by the National Science and Technology Major Project for investigational new drug (2018ZX09201-014), the Beijing Hospitals Authority Clinical Medicine Development of special funding support (XMLX202128), and the University of Macau (MYRG2019-00066-FHS; MYRG2022-00187-FHS).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1272812/ full#supplementary-material

5. Fernández-de-las-Peñas C, de-la-Llave-Rincón AI, Ortega-Santiago R, Ambite-Quesada S, Gómez-Mayordomo V, Cuadrado ML, et al. Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID-19 survivors: A multicenter study. *Pain.* (2022) 163:E989–e996. doi: 10.1097/j.pain.00000000002564

6. Tanriverdi A, Savci S, Kahraman BO, Ozpelit E. Extrapulmonary features of post-COVID-19 patients: muscle function, physical activity, mood, and sleep quality. *Ir J Med Sci.* (2022) 191:969–75. doi: 10.1007/s11845-021-02667-3

7. Jiang ZY, Zhu PP, Wang LY, Hu Y, Pang MF, Ma SS, et al. Psychological distress and sleep quality of COVID-19 patients in Wuhan, a lockdown city as the epicenter of COVID-19. *J Psychiatr Res.* (2021) 136:595–602. doi: 10.1016/j.jpsychires.2020.10.034

8. Zhang L, Li TT, Chen LK, Wu F, Xia WG, Huang M, et al. Association of sleep quality before and after SARS-COV-2 infection with clinical outcomes in hospitalized

patients with Covid-19 in China. EXCLI J. (2021) 20:894-906. doi: 10.17179/ excli2021-3451

9. Akinci T, Basar HM. Relationship between sleep quality and the psychological status of patients hospitalised with COVID-19. *Sleep Med.* (2021) 80:167–70. doi: 10.1016/j.sleep.2021.01.034

10. De Mello MT, Silva A, Guerreiro RD, da-Silva FR, Esteves AM, Poyares D, et al. Sleep and COVID-19: considerations about immunity, pathophysiology, and treatment. *Sleep Sci.* (2020) 13:199–209. doi: 10.5935/1984-0063.20200062

11. Bhat S, Chokroverty S. Sleep disorders and COVID-19. Sleep Med. (2022) 91:253–61. doi: 10.1016/j.sleep.2021.07.021

12. Ahmed GK, Khedr EM, Hamad DA, Meshref TS, Hashem MM, Aly MM. Long term impact of Covid-19 infection on sleep and mental health: a cross-sectional study. *Psychiatry Res.* (2021) 305:114243. doi: 10.1016/j.psychres.2021.114243

13. Amra B, Salmasi M, Soltaninejad F, Sami R, Nickpour M, Mansourian M, et al. Healthcare workers' sleep and mood disturbances during COVID-19 outbreak in an Iranian referral center. *Sleep Breath.* (2021) 25:2197–204. doi: 10.1007/s11325-021-02312-4

14. Li X, Cai Q, Jia Z, Liu L, Zhou Y, Zhang B, et al. The correlation between mental health status, sleep quality, and inflammatory markers, virus negative conversion time among patients confirmed with 2019-nCoV during the COVID-19 outbreak in China An observational study. *Medicine (United States)*. (2021) 100:e26520. doi: 10.1097/MD.00000000026520

15. Rousseau AF, Minguet P, Colson C, Kellens I, Chaabane S, Delanaye P, et al. Postintensive care syndrome after a critical COVID-19: Cohort study from a Belgian followup clinic. *Ann Intensive Care*. (2021) 11:118. doi: 10.1186/s13613-021-00910-9

16. Zhang J, Xu D, Xie B, Zhang Y, Huang H, Liu H, et al. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study. *Brain Behav Immun.* (2020) 88:50–8. doi: 10.1016/j.bbi.2020.05.075

17. Alshumrani R, Qanash S, Aldobyany A, Alhejaili F, Alqassas I, Shabrawishi M, et al. Sleep quality and mental health in coronavirus disease 2019 patients and general population during the pandemic. *Ann Thoracic Med.* (2022) 17:21–7. doi: 10.4103/atm. atm_191_21

18. Li Z, He J, Wang Y, Bai M, Zhang Y, Chen H, et al. A cross-sectional study on the mental health of patients with COVID-19 1 year after discharge in Huanggang, China. *Eur Arch Psych Clin Neurosci.* (2022) 273:301–10. doi: 10.1007/s00406-022-01484-8

19. Delgado-Alonso C, Valles-Salgado M, Delgado-Alvarez A, Yus M, Gomez-Ruiz N, Jorquera M, et al. Cognitive dysfunction associated with COVID-19: A comprehensive neuropsychological study. *J Psychiatr Res.* (2022) 150:40–6. doi: 10.1016/j. jpsychires.2022.03.033

20. Thakur M, Datusalia AK, Kumar A. Use of steroids in COVID-19 patients: A meta-analysis. Eur J Pharmacol. (2022) 914:174579. doi: 10.1016/j.ejphar.2021.174579

21. Srivastava R, Kumar A. Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis. *Int J Clin Pract.* (2021) 75:7. doi: 10.1111/ijcp.14515

22. Thakur M, Babu A, Khatik GL, Datusalia AK, Khatri R, Kumar A. Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis. *World J Meta-Anal.* (2023) 11:125–33. doi: 10.13105/wjma.v11.i4.125

23. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* (2009) 6:6. doi: 10.1371/journal.pmed.1000097

24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Metaanalysis of observational studies in epidemiology - A proposal for reporting. *J Am Med Assoc.* (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008

25. Scarpelli S, Zagaria A, Ratti PL, Albano A, Fazio V, Musetti A, et al. Subjective sleep alterations in healthy subjects worldwide during COVID-19 pandemic: A systematic review, meta-analysis and meta- regression. *Sleep Med.* (2022) 100:89–102. doi: 10.1016/j.sleep.2022.07.012

26. Alkodaymi MS, Omrani OA, Fawzy NA, Abou Shaar B, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. *Clin Microbiol Infect*. (2022) 28:657–66. doi: 10.1016/j.cmi.2022.01.014

27. Deng JW, Zhou FW, Hou WT, Silver Z, Wong CY, Chang O, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. *Ann N Y Acad Sci.* (2021) 1486:90–111. doi: 10.1111/nyas.14506

28. Zhou YF, Yang Y, Shi TY, Song YZ, Zhou YN, Zhang ZB, et al. Prevalence and demographic correlates of poor sleep quality among frontline health professionals in Liaoning Province, China during the COVID-19 outbreak. *Front Psych.* (2020) 11:6. doi: 10.3389/fpsyt.2020.00520

29. Sedov ID, Cameron EE, Madigan S, Tomfohr-Madsen LM. Sleep quality during pregnancy: A meta-analysis. *Sleep Med Rev.* (2018) 38:168–76. doi: 10.1016/j.smrv.2017.06.005

30. Boyle MH. Guidelines for evaluating prevalence studies. *Evid Based Mental Health.* (1998) 1:37–9. doi: 10.1136/ebmh.1.2.37

31. Dong M, Lu L, Zhang L, Zhang QG, Ungvari GS, Ng CH, et al. Prevalence of suicide attempts in bipolar disorder: a systematic review and meta-analysis of

observational studies. *Epidemiol Psychiatr Sci.* (2020) 29:9. doi: 10.1017/ S2045796019000593

32. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z

33. Institute of Medical Biometry and Statistics. R packages. (2023). Available at: http://www.imbi.uni-freiburg.de/lehre/lehrbuecher/meta-analysis-with-r/r-packages (Accessed February 22, 2023).

34. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557

35. Vaseghi N, Sharifisooraki J, Khodadadi H, Nami S, Safari F, Ahangarkani F, et al. Global prevalence and subgroup analyses of coronavirus disease (COVID-19) associated Candida auris infections (CACa): A systematic review and meta-analysis. *Mycoses.* (2022) 65:683–703. doi: 10.1111/myc.13471

36. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. *Ann Rheum Dis.* (2021) 80:384–91. doi: 10.1136/annrheumdis-2020-218946

37. Abbas A, Al-Otaibi T, Gheith OA, Nagib AM, Farid MM, Walaa M. Sleep quality among healthcare workers during the covid-19 pandemic and its impact on medical errors: Kuwait experience. *Turkish Thoracic Journal.* (2021) 22:142–8.

38. Abdelghani M, Alsadik M, Abdelmoaty A, Atwa S, Said A, Hassan M. Sleep disturbances following recovery from COVID-19: a comparative cross-sectional study in Egypt. *Eastern Mediterranean Health Journal*. (2022) 28:14–22.

39. Akova I, Gedikli MA. Fatigue and Sleep Quality Levels of Post-COVID-19 Healthcare Workers and Affecting Factors. *International Journal of Academic Medicine and Pharmacy.* (2022) 4:65–9.

40. Al-Ameri LT, Hameed EK, Maroof BS. Sleep quality in COVID-19 recovered patients. *Sleep Science*. (2022) 15:168–71.

41. Al-Otaibi T, Abbas A, Nagib AM, Gheith OA, Nair P, Farid MM, et al. COVIDsomnia: anxiety, insomnia, and poor sleep among second-line healthcare workers during COVID-19 pandemic. *EGYPTIAN JOURNAL OF BRONCHOLOGY*. (2022) 16

42. Awan I, Balouch AH, Juseja AK, Lakho MA, Shaikh A. Long Term Impact of COVID-19 Infection on Sleep and Mental Health. *Pakistan Journal of Medical and Health Sciences*. (2022) 16:102–4.

43. Benitez ID, Moncusi-Moix A, Vaca R, Gort-Paniello C, Minguez O, Santisteve S, et al. Sleep and Circadian Health of Critical COVID-19 Survivors 3 Months After Hospital Discharge. *Critical care medicine*. (2022) 50:945–54.

44. Bungenberg J, Humkamp K, Hohenfeld C, Rust MI, Ermis U, Dreher M, et al. Long COVID-19: Objectifying most self-reported neurological symptoms. *Annals of Clinical and Translational Neurology.* (2022) 9:141–54.

45. Cacciatore M, Raggi A, Pilotto A, Cristillo V, Guastafierro E, Toppo C, et al. Neurological and Mental Health Symptoms Associated with Post-COVID-19 Disability in a Sample of Patients Discharged from a COVID-19 Ward: A Secondary Analysis. *International Journal of Environmental Research and Public Health*. (2022) 19:4242.

46. Choudhry AA, Shahzeen F, Choudhry SA, Batool N, Murtaza F, Dilip A, et al. Impact of COVID-19 Infection on Quality of Sleep. *Cureus*. (2021) 13:e18182

47. Dai LL, Wang X, Jiang TC, Li PF, Wang Y, Wu SJ, et al. Anxiety and depressive symptoms among COVID-19 patients in Jianghan Fangcang Shelter Hospital in Wuhan, China. *PLoS ONE*. (2020) 15:e0238416.

48. ElHafeez SA, Meira e Cruz M, Gouda S, Nofal M, Fayed A, Ghazy RM, et al. Sleep quality and anxiety among Egyptian population during covid-19 pandemic. Sleep. *Science*. (2022) 15:8–16.

49. Gundogdu N, Tanriverdi M. Sleep Quality of Patients with COVID-19 after Hospital Discharge. *Progress in Nutrition*. (2022) 24:e2022059

50. Gunes A, Sensoy B. Sleepiness, Insomnia, and Sleep Quality of Hospitalized Patients with Coronavirus Disease-2019: Sleep Scale Evaluation. *Journal of Turkish Sleep Medicine*. (2022) 9:11–5.

51. Hartung TJ, Neumann C, Bahmer T, Chaplinskaya-Sobol I, Endres M, Geritz J, et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. *EClinicalMedicine*. (2022) 53:101651

52. Henriquez-Beltran M, Labarca G, Cigarroa I, Enos D, Lastra J, Nova-Lamperti E, et al. Sleep health and the circadian rest-activity pattern four months after COVID-19. *Jornal Brasileiro de Pneumologia*. (2022) 48:e20210398

53. Karaogullarindan A, Erkan SO, Tuhanioglu B, Kuran G, Gorgulu O. Sleep quality in patients over 65 years of age in the covid-19 pandemic. *Turk Geriatri Dergisi*. (2021) 24:381–90.

54. Lin Y, Liu S, Li S, Zuo H, Zhang B. Relationships between the changes in sleep patterns and sleep quality among Chinese people during the 2019 coronavirus disease outbreak. *Sleep Medicine*. (2022) 91:154–60.

55. Malik M, Atiq A, Tahir MJ, Akhtar FK, Malik MI, Hassan W, et al. Comparison of sleep quality among COVID-19 patients and non-COVID-19 population in Pakistan: A cross sectional study during the COVID-19 pandemic. *Annals of Medicine and Surgery.* (2022) 78:103894

56. Nowakowski S, Kokonda M, Sultana R, Duong BB, Nagy SE, Zaidan MF, et al. Association between Sleep Quality and Mental Health among Patients at a Post-COVID-19 Recovery Clinic. *Brain Sciences.* (2022) 12:586.

57. Sljivo A, Juginovic A, Ivanovic K, Quraishi I, Mulac A, Kovacevic Z, et al. Sleep quality and patterns of young West Balkan adults during the third wave of COVID-19 pandemic: A cross-sectional study. *BMJ Open.* (2022) 12:e060381

58. Tanriverdi A, Savci S, Kahraman BO, Ozpelit E. Extrapulmonary features of post-COVID-19 patients: muscle function, physical activity, mood, and sleep quality. *Irish Journal of Medical Science*. (2022) 191:969–75.

59. World Health Organization. (2023). Coronavirus disease (COVID-2019) situation reports. Available at: https://www.who.int (Accessed March 1, 2023).

60. Alimoradi Z, Broström A, Tsang HWH, Griffiths MD, Haghayegh S, Ohayon MM, et al. Sleep problems during COVID-19 pandemic and its' association to psychological distress: A systematic review and meta-analysis. *EClinicalMedicine*. (2021) 36:100916. doi: 10.1016/j.eclinm.2021.100916

61. Yadav P, Yadav P, Kumar SS, Kumar R. Assessment of depression, anxiety, and sleep disturbance in COVID-19 patients at Tertiary Care Centre of North India. *J Neurosci Rural Pract.* (2021) 12:316–22. doi: 10.1055/s-0040-1722811

62. Silva E, Ono BVS, Souza JC. Sleep and immunity in times of COVID-19. *Rev Assoc Med Bras.* (2020) 66:143–7. doi: 10.1590/1806-9282.66.s2.143

63. Voncken SFJ, Feron TMH, Laven S, Karaca U, Beerhorst K, Klarenbeek P, et al. Impact of obstructive sleep apnea on clinical outcomes in patients hospitalized with COVID-19. *Sleep Breath.* (2022) 26:1399–407. doi: 10.1007/s11325-021-02476-z

64. Beltramo G, Cottenet J, Mariet AS, Georges M, Piroth L, Tubert-Bitter P, et al. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study. *Eur Resp J.* (2021) 58:2004474. doi: 10.1183/13993003.04474-2020

65. Ma J, Hua TT, Zeng K, Zhong BL, Wang G, Liu XB. Influence of social isolation caused by coronavirus disease 2019 (COVID-19) on the psychological characteristics of hospitalized schizophrenia patients: a case-control study. *Transl Psychiatry*. (2020) 10:5. doi: 10.1038/s41398-020-01098-5

66. Zhen R, Li L, Li GQ, Zhou X. Social Isolation, loneliness, and mobile phone dependence among adolescents during the COVID-19 pandemic: roles of parent-child communication patterns. *Int J Mental Health Addict*. (2021) 21:1931–45. doi: 10.1007/s11469-021-00700-1

67. Barateau L, Chenini S, Rassu AL, Denis C, Lorber Q, Dhalluin C, et al. Changes in sleep pattern during the COVID-19 lockdown in patients with narcolepsy, idiopathic hypersomnia, and restless legs syndrome. *Neurology*. (2022) 99:E1475–e1485. doi: 10.1212/WNL.0000000000200907

68. Sun NN, Wei LQ, Wang HY, Wang XR, Gao MX, Hu XJ, et al. Qualitative study of the psychological experience of COVID-19 patients during hospitalization. J Affect Disord. (2021) 278:15–22. doi: 10.1016/j.jad.2020.08.040

69. Gordon JM, Magbee T, Yoder LH. The experiences of critical care nurses caring for patients with COVID-19 during the 2020 pandemic: A qualitative study. *Appl Nurs Res.* (2021) 59:151418. doi: 10.1016/j.apnr.2021.151418

70. González-Hijón J, Kähler AK, Frans EM, Valdimarsdóttir UA, Sullivan PF, Fang F, et al. Unravelling the link between sleep and mental health during the COVID-19 pandemic. *Stress Health*. (2023) 39:828–40. doi: 10.1002/smi.3223

71. Chhajer R, Shukla SD. Sleep quality of Covid-19 recovered patients in India. *Neurosci Insights.* (2022) 17:263310552211091. doi: 10.1177/26331055221109174

72. Shapiro GK, Gottfredson N, Leask J, Wiley K, Ganter-Restrepo FE, Jones SP, et al. COVID-19 and missed or delayed vaccination in 26 middle- and high-income countries: An observational survey. *Vaccine*. (2022) 40:945–52. doi: 10.1016/j.vaccine.2021.12.041

73. Kaadan MI, Abdulkarim J, Chaar M, Zayegh O, Keblawi MA. Determinants of COVID-19 vaccine acceptance in the Arab world: a cross-sectional study. *Glob Health Res Policy.* (2021) 6:7. doi: 10.1186/s41256-021-00202-6

74. Cai R, Novosad P, Tandel V, Asher S, Malani A. Representative estimates of COVID-19 infection fatality rates from four locations in India: cross-sectional study. *BMJ Open*. (2021) 11:e050920. doi: 10.1136/bmjopen-2021-050920

75. Tyler CM, McKee GB, Alzueta E, Perrin PB, Kingsley K, Baker FC, et al. A study of older adults' mental health across 33 countries during the COVID-19 pandemic. *Int J Environ Res Public Health.* (2021) 18:15. doi: 10.3390/ijerph18105090

76. Middelkoop HAM, SmildevandenDoel DA, Neven AK, Kamphuisen HA, Springer CP. Subjective sleep characteristics of 1,485 males and females aged

50-93: Effects of sex and age, and factors related to self-evaluated quality of sleep. *J Gerontol ABiol Sci Med Sci.* (1996) 51:M108–15. doi: 10.1093/gerona/51A.3.M108

77. Qiu JY, Shen B, Zhao M, Wang Z, Xie B, Xu YF. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. *Gen Psychiat.* (2020) 33:3. doi: 10.1136/gpsych-2020-100213

78. Losada-Baltar A, Jiménez-Gonzalo L, Gallego-Alberto L, Pedroso-Chaparro MD, Fernandes-Pires J, Márquez-González M. "We Are Staying at Home." Association of self-perceptions of aging, personal and family resources, and loneliness with psychological distress during the lock-down period of COVID-19. J Gerontol Ser B Psychol Sci Soc Sci. (2021) 76:E10–e16. doi: 10.1093/geronb/gbaa048

79. Li SH, Graham BM. Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. *Lancet Psychiatry*. (2017) 4:73–82. doi: 10.1016/S2215-0366(16)30358-3

80. Hohagen F, Rink K, Kappler C, Schramm E, Riemann D, Weyerer S, et al. Prevalence and treatment of insomnia in general-practice-a longitudinal-study. *Eur Arch Psych Clin Neurosci.* (1993) 242:329–36. doi: 10.1007/BF02190245

81. Cellini N, Conte F, De Rosa O, Giganti F, Malloggi S, Reyt M, et al. Changes in sleep timing and subjective sleep quality during the COVID-19 lockdown in Italy and Belgium: age, gender and working status as modulating factors. *Sleep Med.* (2021) 77:112–9. doi: 10.1016/j.sleep.2020.11.027

82. Vuelvas-Olmos CR, Sanchez-Vidana DI, Cortes-Alvarez NY. Gender-based analysis of the association between mental health, sleep quality, aggression, and physical activity among university students during the COVID-19 outbreak. *Psychol Rep.* (2022) 126:2212–36. doi: 10.1177/00332941221086209

83. Del Brutto OH, Mera RM, Costa AF, Recalde BY, Castillo PR. Sleep quality deterioration in middle-aged and older adults living in a rural Ecuadorian village severely struck by the SARS-CoV-2 pandemic. A population-based longitudinal prospective study. *Sleep*. (2021) 44:10.1093/sleep/zsab041:6.

84. Dayaramani C, De Leon J, Reiss AB. Cardiovascular disease complicating COVID-19 in the elderly. *Medicina-Lithuania*. (2021) 57:22. doi: 10.3390/ medicina57080833

85. Dai LS, Xiong F, Li WT. The impact of social quarantine on the living status and mental health of the elderly in the Wuhan community: one year after Wuhan COVID-19 blockade. *BMC Geriatr.* (2022) 22:8. doi: 10.1186/s12877-022-03560-z

86. Lee DY, Cho J, You SC, Park RW, Kim CS, Lee EY, et al. Risk of mortality in elderly coronavirus disease 2019 patients with mental health disorders: a nationwide retrospective study in South Korea. *Am J Geriatr Psychiatr.* (2020) 28:1308–16. doi: 10.1016/j.jagp.2020.09.016

87. Wang L, He WB, Yu XM, Hur DL, Bao MW, Liu HF, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week followup. *J Infect*. (2020) 80:639–45. doi: 10.1016/j.jinf.2020.03.019

88. Rotenstein LS, Ramos MA, Torre M, Segal JB, Peluso MJ, Guille C, et al. Prevalence of depression, depressive symptoms, and suicidal ideation among medical students a systematic review and meta-analysis. *J Am Med Assoc.* (2016) 316:2214–36. doi: 10.1001/jama.2016.17324

89. Zeng LN, Zong QQ, Yang Y, Zhang L, Xiang YF, Ng CH, et al. Gender difference in the prevalence of insomnia: a meta-analysis of observational studies. *Front Psych.* (2020) 11:9. doi: 10.3389/fpsyt.2020.577429

90. Rao WW, Zhu XM, Zong QQ, Zhang QG, Hall BJ, Ungvari GS, et al. Prevalence of prenatal and postpartum depression in fathers: A comprehensive meta-analysis of observational surveys. *J Affect Disord.* (2020) 263:491–9. doi: 10.1016/j.jad.2019.10.030

91. Mata DA, Ramos MA, Bansal N, Khan R, Guille C, Di Angelantonio E, et al. Prevalence of depression and depressive symptoms among resident physicians a systematic review and meta-analysis. *J Am Med Assoc.* (2015) 314:2373–83. doi: 10.1001/jama.2015.15845

92. Bai W, Liu ZH, Jiang YY, Zhang QE, Rao WW, Cheung T, et al. Worldwide prevalence of suicidal ideation and suicide plan among people with schizophrenia: a meta-analysis and systematic review of epidemiological surveys. *Transl Psychiatry.* (2021) 11:10. doi: 10.1038/s41398-021-01671-6

93. Long J, Huang G, Liang W, Liang B, Chen Q, Xie J, et al. The prevalence of schizophrenia in mainland China: evidence from epidemiological surveys. *Acta Psychiatr Scand.* (2014) 130:244–56. doi: 10.1111/acps.12296